Sign In
Buy FDMT
$9.53
+0.260 (+2.80%)
At Close: Jun 03, 2026
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
04:05pm, Thursday, 29'th Feb 2024
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
11:27pm, Tuesday, 06'th Feb 2024
EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of gene
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
04:05pm, Monday, 05'th Feb 2024
EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of gene
Why Is 4D Molecular (FDMT) Stock Up 85% Today?
02:50pm, Monday, 05'th Feb 2024
Some massive winners in the world of biotech companies continue to emerge today. 4D Molecular Therapeutics (NASDAQ: FDMT ) is the latest company to generate massive attention from investors, with FDMT
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
12:41pm, Monday, 05'th Feb 2024
Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy.
EMERYVILLE, Calif., Feb. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
EMERYVILLE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
08:00am, Tuesday, 23'rd Jan 2024
EMERYVILLE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
01:01pm, Friday, 19'th Jan 2024
4D Molecular Therapeutics, Inc. (FDMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
08:00am, Thursday, 04'th Jan 2024
EMERYVILLE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
08:01am, Wednesday, 03'rd Jan 2024
EMERYVILLE, Calif. and CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), a leading clinical-stage genetic medicines company focused on unlocking the
EMERYVILLE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company with three novel, highly targeted next ge
4DMT to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 15'th Nov 2023
EMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generatio
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
08:00am, Wednesday, 25'th Oct 2023
EMERYVILLE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted nex
